Independent Medical Education Funding and Application

As part of Amgen's mission to further the advancement of medicine and healthcare, Amgen supports Independent Medical Education ("IME"). IME is professional education given by accredited medical education providers who design and implement programs totally independent of any Amgen influence, as defined by standards such as the Accreditation Council for Continuing Medical Education ("ACCME") guidelines, the FDA's Guidance: Industry Supported Scientific and Educational Activities, and the PhRMA Code.

Funding requests including for live presentations, written enduring materials, online courses, and conference symposia from organizations (e.g. hospitals, universities, societies, medical-education vendors) will be reviewed and assessed in conjunction with Amgen's goal to help physicians and other healthcare professionals to obtain information and insights that contribute to the improvement of patient care and the advancement of medicine.

Areas of Interest to Amgen

Amgen supports IME that address:

  • Education of health care providers including trainees, allied health professionals and payers
  • Advancing the understanding of the disease state
  • Improving health care providers' understanding of the diagnosis, treatment, outcomes, and co-morbidities
  • Quality, reimbursement, access to care
  • Innovative and biosimilar drug development

Disease States and Areas of Interest:

Global Biomedical Data Sciences

  • Fellowships in Statistics or Biostatistics
  • Annual Society meetings for Statistics, Biostatistics or Statistical Programming
  • Programs in the field of Statistics, Biostatistics or Statistical Programming

Oncology

  • Prostate Cancer
  • MRD in ALL (or acute leukemia) [especially if reaching pathologists and/or community oncologists]
  • Treatment of pediatrics, AYA and adult ALL patients [especially if with global reach]
  • Importance of molecular testing in cancer care with emphasis on NSCLC or CRC
  • Bone health and prevention of skeletal events in cancer
  • Management of ITP
  • Management of relapse and refractory Multiple Myeloma Bispecific T-cell

Bone

  • Burden of disease and clinical consequences of Osteoporotic fractures
  • Improving the awareness, diagnosis, and treatment of Osteoporosis, among multiple specialties (notably primary care and orthopedics) with varying degrees of expertise including advance practice providers
  • Identification and treatment of patients with osteoporosis at high risk for fracture
  • Importance of secondary fracture prevention and education supporting starting and sustaining post fracture care programs
  • Use of non-invasive techniques to assess bone quality, including education on how to interpret DXA
  • New and emerging treatments in osteoporosis, including the evolved treatment paradigm of anabolic → antiresorptive for patients at very high risk of fracture
  • Conditions other than PMO/MOP associated with bone loss and fractures: CTIBL, GIOP, OP with CKD, OP with diabetes, Osteogenesis Imperfecta, and idiopathic OP

Cardiovascular

Dyslipidemia education to increase awareness and (if applicable) consequences of:

  • Identification and management of very high risk ASCVD patients with a focus on ACS and Recent MI
  • Education on the implementation of the 2018 ACC/AHA Cholesterol Guidelines
  • Current Dyslipidemia treatment landscape and the importance and urgency of LDL-C lowering in CVD
  • Enhancing patient access to PCSK9 inhibitors and improving physician perception

Inflammation

  • Rheumatologic diseases with particular interest in: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Juvenile Idiopathic Arthritis
  • Dermatologic diseases focusing on Psoriasis and other psoriatic diseases
  • Other inflammatory diseases including lupus and related autoimmune diseases
  • Inflammatory bowel disease
  • Asthma
  • Education about the biosimilar approval pathway, biologic manufacturing and biosimilar development

Nephrology

  • Anemia associated with CKD-treatment, consequences, transfusion, risk: benefit of treatment
  • CKD Mineral and Bone Disorder – pathogenesis, consequences, treatment
  • Emerging data (clinical and basic research)
  • Quality improvement in the care of patients with renal disease
  • Healthcare disparities
  • Emerging trends in Pharmacoeconomics and healthcare policy research pertaining to CKD
  • Advancement of the field of pharmacy through education

Neuroscience

Migraine education to increase awareness of:

  • Burden of disease and clinical consequences of migraine
  • Treatment options for migraine and its unmet needs
  • Impact of migraine on healthcare resource utilization
  • Patient reported outcomes (PROs) for migraine
  • Advancement of the field of pharmacy through education

Pharmacy

Advancement of the field of pharmacy through education


Process Development

Programs that support awareness and education of researchers, students and clinicians in the fields involved in process development, of large molecules, oral parenterals and other novel therapeutics:

  • Candidate and molecule selection
  • Manufacture and characterization (upstream and downstream, synthetic) of drug substance
  • Manufacture and characterization of drug product
  • Device development
  • Quality target product profile and identification of critical quality attributes
  • Society activities involved in education, career development, and scientific exchange in process, product, and device development
  • Programs dedicated to educating and training students in the various areas involved in product development

Translational Sciences

Programs that support awareness and education of clinicians, researchers and patients in the following areas:

  • Comparative Biology and Safety Sciences
  • Medical Sciences
  • Pharmacokinetics and Drug Metabolism
  • Advance field of Translational Sciences focusing on new areas for professional development
  • Education and training of students through didactic and experiential opportunities

Overview of IME Funding Application Process

Amgen is dedicated to making the application process simple and straightforward. Amgen will send an email confirmation upon receipt of your application and documentation.

IME Application Requirements

Amgen's IME funding application process includes:

  • NEW: Effective March 1, 2017 requests for IME funding may be submitted at any time and for any start date, provided that the program start date is 60 days or more from the date of submission. 
  • Amgen requires that an agreement is fully executed prior to the start date of the program content development or activity.  Please plan ahead to ensure a decision and contract execution, if approved, can be completed to meet your deadline.
  • Attachment of the following required documents (in .pdf format) to the application:
    • Letter of Request on the requesting organization's letterhead which includes the following:
      • Must be addressed to Amgen
      • Signed and Dated
      • Program title, date(s), and location(s)
      • Description of the proposed activity
      • Identification of the target audience and projected number of attendees
      • Name of accrediting body and accredited provider, including type and number of medical education credits offered for the proposed activity (program MUST be accredited)
      • If applicable, identification of co-requesting organization(s), medical education partner(s), and/or logistical partner. Please include contact information for these organizations.
    • Needs Assessment (can be included in the Letter of Request)
    • Educational Objectives (can be included in the Letter of Request)
    • Agenda (draft acceptable)
    • Full Program Budget
    • Amgen/ Requested Amount Budget
      (Please Note: Amgen does not prohibit organizers from serving meals at IME events; however, Amgen's IME funds cannot be used to provide meals at IME events)
    • Current IRS W9 form (must be signed and dated within the last 12 months)

Please note that submitting a request does not guarantee you and/or your organization will receive IME funding.

Eligibility Criteria - Important Application Considerations

Independent Medical Education supported by Amgen in the U.S. MUST be:

  • Provided by a United States based accredited provider (e.g. ACCME, ACPE, ANCC) or other organizations authorized by state law to award continuing medical education credits.
  • Paid to a United States based organization

It is important to note:

  • Amgen will not provide IME funding for:
    • Individuals
    • Requests for payments to Individuals
    • Fellowships
    • Overhead Expenses
    • General Operating Expenses
    • Entertainment Expenses
    • Awards/ Travel Awards
    • Costs of travel, lodging, or other personal expenses of non-faculty individuals attending IME, either directly to the individuals participating in the event or indirectly to the event's provider. Funding cannot be used to compensate participants for time spent at the IME event.
    • Meals
      • Amgen does not prohibit organizers from serving meals at IME events; however, Amgen's IME funds shall not be used to provide meals at IME events.
  • Amgen's support for IME programs that meet the Eligibility Criteria is compliant with federal and state laws, as well as guidelines that govern such activities.
  • Amgen commercial staff, including field staff, is not involved in decisions to fund IME programs. For more information regarding Amgen's interactions with healthcare professionals and other customers, (click here).
  • Responsibility and control over the selection, content, faculty, educational methods, materials, and venue for an independent medical education event belongs solely to the organizers of the event in accordance with the accredited provider's guidelines. Amgen will not provide any advice or guidance to the accredited independent medical education provider (even if asked) regarding the content or faculty for any Independent Medical Education program.
  • IME funding decisions will not take into account the current or potential customer status of the IME requestor.
  • Amgen requires that a fully-executed agreement, signed by the requesting IME Provider and Amgen be completed prior to the commencement of the IME program.
  • For funding requests approved by Amgen, the IME funding recipient is required to confirm the completion of the activity and provide documentation of how the funds were used within 60 days after the completion of the independent medical education activity. Documentation should be sent to hccime@amgen.com for reconciliation.

Please note that submitting a request does not guarantee you and/or your organization will receive IME funding.